Catalyst
Slingshot members are tracking this event:
Blueprint Medicines'(BPMC) Pralsetinib Treatment of RET-Mutant Medullary Thyroid Cancer and RET Fusion-Positive Thyroid Cancer PDUFA Date due February 28, 2021
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BPMC | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 01, 2020
Occurred Source:
http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-fda-approval-gavretotm-0
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pralsetinib, Ret-mutant Medullary Thyroid Cancer, Ret Fusion-positive Thyroid Cancer
